Similarly, a TGR5 agonist that is capable of inducing the secretion of GLP-1 as well as increasing energy expenditure may prove to be a promising incretin-based strategy for the treatment of type 2 diabetes and obesity [26,27]. Here, GPBAR1 is linked to obesity due to melanocortin 4 receptor deficiency.